IN2012DN03023A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03023A
IN2012DN03023A IN3023DEN2012A IN2012DN03023A IN 2012DN03023 A IN2012DN03023 A IN 2012DN03023A IN 3023DEN2012 A IN3023DEN2012 A IN 3023DEN2012A IN 2012DN03023 A IN2012DN03023 A IN 2012DN03023A
Authority
IN
India
Prior art keywords
salts
treatment
pharmaceutical compositions
well
cognitive impairment
Prior art date
Application number
Inventor
Yuri Bereznitski
Mark A Huffman
Joseph E Lynch
Matthew Zhao
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IN2012DN03023A publication Critical patent/IN2012DN03023A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Novel crystalline salts of 3-[l-(4-chlorophenyl)-trans-3-fluorocyclobutyl]-4,5-dicyclopropyl-r-4H-l,2,4-triazole are potent inhibitors of 11 ß-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
IN3023DEN2012 2004-01-26 2005-01-21 IN2012DN03023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53920604P 2004-01-26 2004-01-26
PCT/US2005/001928 WO2005073200A1 (en) 2004-01-26 2005-01-21 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1

Publications (1)

Publication Number Publication Date
IN2012DN03023A true IN2012DN03023A (en) 2015-07-31

Family

ID=34826043

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3023DEN2012 IN2012DN03023A (en) 2004-01-26 2005-01-21

Country Status (8)

Country Link
US (1) US7875642B2 (en)
EP (1) EP1711477A4 (en)
JP (1) JP2007519726A (en)
CN (1) CN1910161A (en)
AU (1) AU2005207925B2 (en)
CA (1) CA2553345C (en)
IN (1) IN2012DN03023A (en)
WO (1) WO2005073200A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
WO2007038452A1 (en) * 2005-09-28 2007-04-05 Merck & Co., Inc. Process for synthesizing 1,2,4-triazoles
BRPI0710479A2 (en) 2006-01-18 2012-08-14 Hoffmann La Roche compound, process for its preparation, pharmaceutical composition, use of a compound and method of treating disease or metabolic disorder.
TW200800898A (en) 2006-02-07 2008-01-01 Wyeth Corp 11-Beta HSD1 inhibitors
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2012041013A1 (en) * 2010-10-01 2012-04-05 Shan Dong Luye Pharmaceutical Co., Ltd. Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1037880E (en) 1997-12-11 2004-11-30 Janssen Pharmaceutica Nv MIMETIC ANILIDES OF RETINOIC ACID
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US20030073850A1 (en) 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2003004497A1 (en) 2001-07-05 2003-01-16 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compound
CA2474168A1 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (en) * 2002-06-10 2005-03-23 Merck & Co Inc INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA

Also Published As

Publication number Publication date
EP1711477A1 (en) 2006-10-18
WO2005073200A1 (en) 2005-08-11
US20090186928A1 (en) 2009-07-23
CN1910161A (en) 2007-02-07
CA2553345C (en) 2011-11-15
EP1711477A4 (en) 2009-06-10
AU2005207925A1 (en) 2005-08-11
JP2007519726A (en) 2007-07-19
AU2005207925B2 (en) 2008-09-04
CA2553345A1 (en) 2005-08-11
US7875642B2 (en) 2011-01-25

Similar Documents

Publication Publication Date Title
IN2012DN03023A (en)
WO2007124337A8 (en) Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1
WO2007127726A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127688A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JO3042B1 (en) Cyclohexylpyrazole-Lactam Derivatives as inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1
WO2007127763A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2029529T3 (en) Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PT1960352E (en) 2-adamantylurea derivatives as selective 11beta-hsd1 inhibitors
TNSN08432A1 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL1807072T3 (en) Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
SI2049475T1 (en) Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2007008239A (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme.
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
IL213425A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
JO2397B1 (en) Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
ATE556050T1 (en) INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 ENZYME
TW200505919A (en) DPP-IV inhibitors
SE0403006D0 (en) New compounds
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
TW200806311A (en) Neuropeptide-2 receptor-agonists
NO20072608L (en) Biaryloksymetylarenkarboksylsyrer
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
EP2269977A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme